Berkshire Hathaway Vice-Chairman Charlie Munger had some harsh words to say about Valeant Pharmaceuticals. » Read More
Former Turing Pharmaceuticals executive Martin Shkreli will appear before Congress this morning, reports CNBC's Meg Tirrell.
After his hearing at Brooklyn court on Wednesday, Martin Shkreli will no longer be speaking to the press according to his new lawyer.
Merck reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment.
U.K. drug store Boots has cut the prices on some of its products after it emerged it was charging women more than men for similar products.
Gilead Sciences Q4 EPS beat analysts' expectations, reports CNBC's Meg Tirrell.
Gilead reported quarterly earnings and revenue on Tuesday that beat analysts' expectations, boosted by sales of its drugs in Japan.
Kadmon, the biotechnology company founded by ImClone's Sam Waksal, is preparing to file confidentially for an initial public offering, sources say.
Sam Isaly, OrbiMed Advisors, discusses the biotech sector and how cases like the Zika virus impact the health sector.
A possible vaccine for the Zika virus is still three to 10 years away, says Max Macaluso, an analyst at The Motley Fool.
Tourism and travel-related stocks have taken a hit from worries surrounding the Zika virus.
The Zika virus spreads through mosquitoes and can cause feverish symptoms and even birth defects. Oxitec, a subsidiary of Intrexon, is working on a genetically modified mosquito to help combat spreading the virus, with Intrexon CEO Randal Kirk.
The Zika virus should not cause Americans to be "unduly alarmed just yet," says infectious disease expert Paul Roepe.
Gilead Sciences on Friday that John Milligan, currently president and chief operating officer, will be promoted to CEO and appointed to the board of directors.
Amgen boosted guidance after it beat on fourth-quarter earnings, helped by sales of its rheumatoid arthritis drug Enbrel.
Massachusetts Attorney General Maura Healey explains why it's worth investigating drug pricing and Gilead's practices.
The rap-fueled beef with Ghostface Killah was recorded while the pharma exec Martin Shkreli is free on $5 million bond.
Health care is one of the biggest drags on the market right now because of the moves lower in biotech stocks. CNBC's Meg Tirrell looks ahead to biotech earnings out next week. The FMHR traders and Kate Moore, JPMorgan Private Bank chief investment strategist, discuss.
Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.
Severin Schwan, CEO of Roche, discusses his company's full year results, which came in below expectations.
The rapid spread of the zika virus has spurred the hunt for a cure, but the financial incentive and likely length of time for a vaccine are unclear.
Get the best of CNBC in your inbox